October 25, 2014 11:28 AM ET


Company Overview of E. Claiborne Robins Company, Inc.

Company Overview

E. Claiborne Robins Company, Inc., doing business as ECR Pharmaceuticals, manufactures and sells pharmaceutical products to healthcare professionals and patients. It offers products for the treatment of symptoms related to allergy, cough and cold, analgesics, and poison ivy and dermatitis; Zolpimist Oral Spray, a delivery system of prescribed sleep aid; and Lodrane D, an adult brompheniramine. The company also provides patient assistance programs. It sells its products through wholesale suppliers. E. Claiborne Robins Company, Inc. was founded in 1990 and is based in Richmond, Virginia. As of June 20, 2014, E. Claiborne Robins Company, Inc. operates as a subsidiary of Valeant Pharmaceuticals ...

3969 Deep Rock Road

Richmond, VA 23233

United States

Founded in 1990





Key Executives for E. Claiborne Robins Company, Inc.

Chief Executive Officer and President
Age: 53
Executive Chairman
Age: 58
Compensation as of Fiscal Year 2014.

E. Claiborne Robins Company, Inc. Key Developments

ECR Pharmaceutical Co., Inc. Announces Management Changes

Davis Caskey, Vice President Pharmaceutical Operations of ECR Pharmaceutical Co., Inc., a wholly owned subsidiary of the Company, has announced that he will be retiring from the company effective March 31, 2013. On March 11, 2013, the company appointed Cameron Durrant to the positions of President and Chief Executive Officer pursuant to an employment agreement. Dr. Durrant has been a consultant for the company for the past six months and worked in the pharmaceutical industry for 22 years, and in medical practice for 8 years prior. He has been CEO or interim CEO for four venture-backed companies and CFO of a public company. He has been a senior executive at Johnson and Johnson, Pharmacia Corporation (until its acquisition by Pfizer), GSK and Merck.

E. Claiborne Robins Company, Inc. Announces Sales Results for the Second Quarter 2013

E. Claiborne Robins Company, Inc. announced sales results for the second quarter 2013. For the quarter, sales rose 59% to $5.6 million from $3.5 million in the prior year. The increase was led by Bupap, which had strong unit sales ahead of announced price increase in the month of September.

Similar Private Companies By Industry

Company Name Region
EyeScience Labs, LLC United States
NorthStar Biotech, LLC United States
LifeTein LLC United States
Akorn (New Jersey), Inc. United States
Orphagen Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

June 20, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact E. Claiborne Robins Company, Inc., please visit www.ecrpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.